Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

RPRX – Royalty Pharma plc

Royalty Pharma plc
RPRX
$37.11
Name : Royalty Pharma plc
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $20,864,727,040.00
EPSttm : 2.45
finviz dynamic chart for RPRX
Royalty Pharma plc
$37.11
0.84%
$0.31

Float Short %

5.04

Margin Of Safety %

36

Put/Call OI Ratio

0.17

EPS Next Q Diff

0.35

EPS Last/This Y

2.48

EPS This/Next Y

0.62

Price

37.11

Target Price

43

Analyst Recom

1.33

Performance Q

14.25

Relative Volume

0.41

Beta

0.54

Ticker: RPRX




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-07-04RPRX36.460.200.0032764
2025-07-07RPRX35.590.200.0732673
2025-07-08RPRX35.510.200.2932945
2025-07-09RPRX35.870.200.0232935
2025-07-10RPRX36.120.200.0032963
2025-07-11RPRX35.850.200.0032932
2025-07-14RPRX36.240.200.0032938
2025-07-15RPRX36.520.200.0032976
2025-07-16RPRX35.60.200.0033056
2025-07-17RPRX35.470.200.0133062
2025-07-18RPRX35.580.200.0033085
2025-07-21RPRX35.660.180.0420004
2025-07-22RPRX36.090.180.0020117
2025-07-23RPRX36.030.180.0420197
2025-07-24RPRX36.60.180.0020267
2025-07-25RPRX36.690.180.0020274
2025-07-28RPRX37.080.180.1320284
2025-07-29RPRX37.270.170.0120472
2025-07-30RPRX37.120.170.0120573
2025-07-31RPRX36.810.170.0220726
2025-08-01RPRX37.120.170.6720919
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-07-04RPRX36.378.6208.84.41
2025-07-07RPRX35.588.6166.14.41
2025-07-08RPRX35.518.6197.14.41
2025-07-09RPRX35.878.6216.94.41
2025-07-10RPRX36.128.6211.94.41
2025-07-11RPRX35.848.6199.44.41
2025-07-14RPRX36.248.6218.64.41
2025-07-15RPRX36.518.6212.74.41
2025-07-16RPRX35.608.6160.74.41
2025-07-17RPRX35.478.6194.94.41
2025-07-18RPRX35.588.6205.74.41
2025-07-21RPRX35.668.6203.94.41
2025-07-22RPRX36.098.6220.44.41
2025-07-23RPRX36.018.6196.74.41
2025-07-24RPRX36.598.6226.64.41
2025-07-25RPRX36.676.4204.24.40
2025-07-28RPRX37.056.4217.44.40
2025-07-29RPRX37.276.4209.94.40
2025-07-30RPRX37.126.4194.74.40
2025-07-31RPRX36.806.4186.84.40
2025-08-01RPRX37.116.4214.34.40
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-07-04RPRX0.00-0.178.74
2025-07-07RPRX0.00-0.138.74
2025-07-08RPRX0.00-0.138.74
2025-07-09RPRX0.00-0.138.74
2025-07-10RPRX0.00-0.138.74
2025-07-11RPRX0.00-0.135.09
2025-07-14RPRX0.000.445.09
2025-07-15RPRX0.000.445.09
2025-07-16RPRX0.000.445.09
2025-07-17RPRX0.000.445.09
2025-07-18RPRX0.000.445.09
2025-07-21RPRX0.000.285.09
2025-07-22RPRX0.000.285.09
2025-07-23RPRX0.000.285.09
2025-07-24RPRX0.000.285.09
2025-07-25RPRX0.000.285.04
2025-07-28RPRX0.00-0.265.04
2025-07-29RPRX0.00-0.265.04
2025-07-30RPRX0.00-0.265.04
2025-07-31RPRX0.00-0.265.04
2025-08-01RPRX0.00-0.265.04
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

0.65

Avg. EPS Est. Current Quarter

1.04

Avg. EPS Est. Next Quarter

1

Insider Transactions

Institutional Transactions

-0.26

Beta

0.54

Average Sales Estimate Current Quarter

725

Average Sales Estimate Next Quarter

767

Fair Value

50.34

Quality Score

72

Growth Score

84

Sentiment Score

98

Actual DrawDown %

30.3

Max Drawdown 5-Year %

-49.7

Target Price

43

P/E

15.13

Forward P/E

7.39

PEG

1.39

P/S

9.22

P/B

2.36

P/Free Cash Flow

7.57

EPS

2.45

Average EPS Est. Cur. Y​

4.4

EPS Next Y. (Est.)

5.03

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

48.24

Relative Volume

0.41

Return on Equity vs Sector %

-7.4

Return on Equity vs Industry %

11.2

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.02

EBIT Estimation

214.3
Royalty Pharma plc
Sector: Healthcare
Industry: Biotechnology
Employees:
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
stock quote shares RPRX – Royalty Pharma plc Stock Price stock today
news today RPRX – Royalty Pharma plc stock forecast ,stock prediction 2023 2024 2025
marketwatch RPRX – Royalty Pharma plc yahoo finance google finance
stock history RPRX – Royalty Pharma plc invest stock market
stock prices RPRX premarket after hours
ticker RPRX fair value insiders trading